Pyrroles
Search Within Results
1
–
2
of
2
results
1
Medchemexpress LLC Tlr7/8/9-in-1 | 2180127-82-4 | 98.5% | C27H37N3O2 | 10MG
TLR7/8/9-IN-1 is a potent, orally bioavailable small-molecule antagonist of Toll-like receptors 7, 8, and 9 intended for research use in immunology and inflammation studies. It inhibits TLR-mediated signaling in cellular assays and demonstrates low-nanomolar antagonist activity in PBMCs, supporting mechanistic and preclinical investigations.
- Potent antagonist with IC50 = 43 nM against TLR7/8/9.
- Low-nanomolar activity in PBMCs (TLR7 IC50 = 4.8 nM; TLR9 IC50 = 510 nM).
- Orally bioavailable small molecule suitable for in vivo and in vitro studies.
- High purity (98.51%) appropriate for biochemical assays.
- Available as solid and as 10 mM in DMSO solutions for flexible dosing.
2
Medchemexpress LLC Tlr7/8/9-in-1 | 2180127-82-4 | 98.5% | 435.60 g/mol | C27H37N3O2 | 5 MG
TLR7/8/9-IN-1 is a potent, orally bioavailable small-molecule antagonist of Toll-like receptors 7, 8, and 9 used in preclinical studies to inhibit TLR signaling and downstream cytokine release. The compound is supplied as a high-purity solid with published in vitro and in vivo solubility and activity data.
- Potent antagonist activity (IC50 = 43 nM in TLR7/8/9 assays)
- Demonstrates 4.8 nM potency versus TLR7 in PBMC IL-6 reduction
- High reported purity of 98.5%
- Molecular weight 435.60 g/mol; formula C27H37N3O2
- Solid, off-white to light-yellow physical appearance
- Soluble in DMSO (83.33 mg/mL) and formulated for in vivo use (≥2.08 mg/mL)
- Suitable for preclinical studies of TLR pathway modulation